Vivacta is developing next-generation in vivo CAR-T therapies, with its lead program GT801 focused on hematologic malignancies and autoimmune diseases. Early clinical data reported at ASH 2025 indicated promising safety and efficacy signals for GT801. The company plans to use new financing to advance GT801 clinical trials, pursue regulatory submission and approval, expand its research team and platform, and drive global expansion. Vivacta describes its investor base as a mix of global industrial capital and specialist biotech investors, and raised over US$50 million in its Series A and Series A+ financings. After the financing, representatives from Loyal Valley Capital and DC Global Ventures joined the board, signaling investor engagement in governance and strategy.

Total raised

$50M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2026